1265 related articles for article (PubMed ID: 19118249)
21. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry.
Zahn R; Hamm CW; Schneider S; Zeymer U; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Sabin G; Nienaber CA; Senges J;
Am Heart J; 2006 Dec; 152(6):1146-52. PubMed ID: 17161068
[TBL] [Abstract][Full Text] [Related]
22. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Han YL; Wang B; Li Y; Xu K; Wang SL; Jing QM; Wang ZL; Wang DM; Ma YY; Wang G
Chin Med J (Engl); 2009 Apr; 122(7):793-7. PubMed ID: 19493391
[TBL] [Abstract][Full Text] [Related]
23. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
24. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
[TBL] [Abstract][Full Text] [Related]
26. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
27. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
28. Letter by de Miguel Castro et al regarding article, "cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up".
de Miguel Castro A; Diego Nieto A; Pérez de Prado A
Circulation; 2009 Sep; 120(13):e98; author reply e99. PubMed ID: 19786639
[No Abstract] [Full Text] [Related]
29. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
30. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
[TBL] [Abstract][Full Text] [Related]
31. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
32. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
34. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era.
Agema WR; Monraats PS; Zwinderman AH; De Winter RJ; Tio RA; Doevendans PA; Waltenberger J; De Maat MP; Frants RR; Atsma DE; Van Der Laarse A; Van Der Wall EE; Jukema JW
Eur Heart J; 2004 Jul; 25(13):1163-70. PubMed ID: 15231375
[TBL] [Abstract][Full Text] [Related]
35. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
37. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
[TBL] [Abstract][Full Text] [Related]
38. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
Gurbel PA; Antonino MJ; Bliden KP; Dichiara J; Suarez TA; Singla A; Tantry US
Platelets; 2008 Dec; 19(8):595-604. PubMed ID: 19012177
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of patients of over 85 years old with acute coronary syndrome undergoing percutaneous coronary stenting: a comparison of bare metal stent and drug eluting stent.
Ma HY; Zhou YJ; Dick RJ; Shi DM; Liu YY; Cheng WJ; Guo YH; Wang JL; Ge HL
Chin Med J (Engl); 2008 May; 121(10):887-91. PubMed ID: 18706201
[TBL] [Abstract][Full Text] [Related]
40. Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting.
Huczek Z; Filipiak KJ; Kochman J; Michalak M; Roik M; Grabowski M; Opolski G
Platelets; 2011; 22(7):521-9. PubMed ID: 21443410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
